Cooperative group research efforts in lung cancer 2008: Focus on advanced-stage non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 6, 2008, Pages 346-351

  Wakelee, Heather ^a   Kernstine, Kemp ^b   Vokes, Everett ^c   Schiller, Joan ^d   Baas, Paul ^e   Saijo, Nagahiro ^f   Adjei, Alex ^g   Goss, Glenwood ^h   Gaspar, Laurie ⁱ   Gandara, David R ^j   Choy, Hak ^d   Putnam, Joe Bill ^k  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h OTTAWA REGIONAL CANCER CENTRE   (Canada)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VANDERBILT UNIVERSITY   (United States)

more..

Author keywords

Chemotherapy; Clinical trials; Epidermal growth factor receptor; Fluorescence in situ hybridization

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; ERLOTINIB; K RAS PROTEIN; PACLITAXEL; VANDETANIB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTINUING EDUCATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PREDICTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 59449106057     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.050     Document Type: Article

References (24)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
2. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470-84.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-53.
4. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analy-sis of the published literature. J Clin Oncol 2005; 23:2926-36.
5. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:277S-89S.
6. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23:190-6.
7. Lilenbaum R, Wang X, Gu L, et al. Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2-CALGB 30402. J Clin Oncol 2007; 25(18 suppl):408s (Abstract 7595).
8. Edelman MJ, Watson DM, Wang X, et al. Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. J Clin Oncol 2006; 24(18 suppl):370s (Abstract 7025).
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
10. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-9.
11. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
12. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
13. Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine and carboplatin in advanced non-small cell lung cancer: updated report with survival. J Clin Oncol 2007; 25(18 suppl):388s (Abstract LBA7516).
14. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008; 26(15 suppl):426s (Abstract 8011).
15. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small- cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007; 99:838-46.
16. Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008; 26(15 suppl):427s (Abstract 8014).
17. Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum- doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol 2008; 26(15 suppl):427s (Abstract LBA8012).
18. Mandrekar SJ, Hillman SL, Allen Ziegler KL, et al. Comparison of progression- free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): a North Central Cancer Treatment Group (NCCTG) investigation. J Clin Oncol 2008; 26(15 suppl):429s (Abstract 8021).
19. Patel JD, Hensing TA, Rademaker F, et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non -squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):434s (Abstract 8044).
20. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8.
21. Lynch TJ, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab (Erbitux(R)) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/ metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2:S340 (Abstract B3-03).
22. Pirker R, Szczesna A, von Pawel J, et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(15 suppl):6s (Abstract 3).
23. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-7.
24. Davies AM, Lara PN, Lau DH, et al. Intermittent erlotinib in combination with docetaxel (DOC): Phase I schedules design to achieve pharmacodynamic separation. J Clin Oncol 2005; 23(16 suppl):630s (Abstract 7038).